Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $6.65 per share for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-14
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-06-30 was $86.59.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.07, a 90.51% decline year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $11.27, a 11.47% increase year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $10.11, a 494.71% increase year-over-year.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2026 was $6.65.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $4.14, a 65.12% decline from fiscal 2023.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $11.87, a 13.70% increase from fiscal 2022.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $10.44, a 14.98% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $6.65 10-K · filed 2026-08-14 | ||||
| 2025-12-31 | $5.56 10-Q · filed 2026-03-09 | ||||
| 2025-09-30 | $3.72 10-Q · filed 2025-11-26 | ||||
| 2025-06-30 | $86.59 10-QT · filed 2025-09-10 | ||||
| 2025-03-31 | $1.07 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $4.14 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | $4.43 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $3.05 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $11.27 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $11.87 10-K/A · filed 2024-05-14 | ||||
| 2023-09-30 | $11.51 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $10.92 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $10.11 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $10.44 10-K/A · filed 2024-05-14 | ||||
| 2022-09-30 | $1.57 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $2.67 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $1.70 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $12.28 10-K · filed 2023-03-31 | $3.07 10-K · filed 2022-04-07 | |||
| 2021-09-30 | $3.15 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $3.32 10-Q · filed 2021-08-16 | ||||
| 2021-03-31 | $4.70 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $1.75 10-K · filed 2021-03-25 | ||||
| 2020-09-30 | $1.39 10-Q · filed 2020-11-16 | ||||
| 2020-06-30 | $1.74 10-Q · filed 2020-08-14 | ||||
| 2020-03-31 | $1.36 10-Q · filed 2020-06-18 | ||||
| 2019-12-31 | $1.46 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $1.35 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $1.39 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $1.39 10-Q · filed 2019-05-16 | ||||
| 2018-12-31 | $1.29 10-K · filed 2020-04-29 | ||||
| 2018-09-30 | $1.27 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $1.25 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | $1.52 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | $1.36 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |